FDA Warns Of Aluminum Toxicity Risk In Infants From Unapproved Potassium Phosphates Drug, Notes Some Hospitals Still Using Hospira's Product; Hospira Agrees To Stop Distribution Within 90 Days
Portfolio Pulse from Benzinga Newsdesk
The FDA has issued a warning about the risk of aluminum toxicity in infants from an unapproved potassium phosphates drug. Some hospitals are still using Hospira's product, but Hospira has agreed to stop distribution within 90 days.
August 21, 2024 | 4:57 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The FDA has warned about aluminum toxicity risks in infants from an unapproved potassium phosphates drug by Hospira, a Pfizer subsidiary. Hospira will cease distribution within 90 days.
The FDA's warning about aluminum toxicity in infants from Hospira's drug could negatively impact Pfizer's reputation and lead to regulatory scrutiny. The decision to stop distribution may mitigate some risks, but the immediate impact is likely negative.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80